Thus, in contrast to phospho-acetyl switch that inhibits STAT1 transcription activity upon its acetylation, AR seems to use both the modifications to allow prostate cancer to evolve through progressive stages to become CRPC. This evidence concerns the gene AR and prostate carcinoma.